Yeda Research and Develpment & Co. Ltd

Universitatsklinikum Hamburg-Eppendorf

Mor Research Applications Ltd.

Meirav Pevsner-Fischer

Irun R Cohen

Raanan Margalit

Johannes Herkel

Eran Ovadia

David Margel

Jack Baniel

Ofer Yossepowitch

The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogues and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers.

Use of AKT phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same

The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogs and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers.

The present invention is directed to the field of cancer diagnosis, specifically to the diagnosis of bladder cancer (BC) and prostate cancer (CaP). More specifically, the invention provides simple, non-invasive urinary tests characterized by high sensitivity and specificity, wherein urinary levels of heat shock proteins and anti-inflammatory cytokines are used as biomarkers.

Urinary biomarkers for cancer diagnosis

Growing community of inventors

Nes Ziona, Israel

Meirav Pevsner-Fischer